The 3 most recent market catalysts affecting $NBTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 95
Nanobiotix H1 EPS $(0.82) Down From $(0.12) YoY, Sales $6.533M Down From $30.202M YoY
Nanobiotix (NBTX) disclosed a substantial deterioration in its financial performance for the first half, with EPS falling from $(0.12) to $(0.82) and sales plummeting from $30.202 …
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 65
Guggenheim Assumes Nanobiotix at Buy, Announces Price Target of $64
Guggenheim analyst Paul Jeng has initiated coverage on Nanobiotix (NBTX) with a 'Buy' rating and a $64 price target. This is a significant event for NBTX as new analyst coverage, e…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Nanobiotix Says JNJ-1900 (NBTXR3) Shows 61% One-Year Local Progression-Free Survival And 70% One-Year Overall Survival In Phase 1 NSCLC Trial
Nanobiotix reported encouraging one-year data from its Phase 1 trial of JNJ-1900 (NBTXR3) for non-small cell lung cancer (NSCLC). The drug demonstrated a 61% one-year local progres…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.